title: T1 and T2 lip cancer: a superselective method of facial arterial infusion therapy--preliminary experience.
abstract: OBJECTIVE
  To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell lip carcinoma.
  
  
  METHODS
  The study included six patients (age range, 46-84 years) with squamous cell carcinoma of the lower lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1-7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1-5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed.
  
  
  RESULTS
  Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during peplomycin sulfate treatment, and another had transient partial hair loss. No disfigurement, recurrence, or late complications were observed at a mean follow-up of 5.0 years (range, 2.3-11.2 years).
  
  
  CONCLUSIONS
  The described facial arterial infusion chemotherapy appears to be a safe and curative treatment for T1 and T2 squamous cell lip carcinomas.
authors.affiliation: Department of Radiology, Wakayama Medical College, Japan. SachiKishi@aol.com
authors.forename: K
authors.initials: K
authors.lastname: Kishi
authors.forename: M
authors.initials: M
authors.lastname: Matsunaka
authors.forename: M
authors.initials: M
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Sonomura
authors.forename: M
authors.initials: M
authors.lastname: Sakurane
authors.forename: K
authors.initials: K
authors.lastname: Uede
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015901:Angiography, Digital Subtraction; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects; D008048:Lip Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008438:Maxillary Artery; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D017663:Peplomycin / Q000008:administration & dosage; D015641:Radiography, Interventional
chemical_list: D016685:Mitomycin; D017663:Peplomycin; D002945:Cisplatin